Neuroprotective agents for the treatment of acute ischemic stroke

被引：103
作者：
Bruce Ovbiagele
Chelsea S. Kidwell
Sidney Starkman
Jeffrey L. Saver
机构：
[1] Stroke Center, Department of Neurology, University of California, Los Angeles, CA 90095
来源：
Current Neurology and Neuroscience Reports | 2003年 / 3卷 / 1期
关键词：
Acute Stroke; Acute Ischemic Stroke; Piracetam; NMDA Antagonist; Human Clinical Trial;
D O I：
10.1007/s11910-003-0031-z
中图分类号：
学科分类号：
摘要：
Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：9 / 20
页数：11
相关论文
共 78 条
[1]  
Lutsep H.L., Clark W.M., Neuroprotection in acute ischemic stroke. Current status and future potential, Drugs Res. Dev., 1, pp. 3-8, (1999)
[2]  
Kristian T., Siesjo B.K., Calcium in ischemic cell death, Stroke, 29, pp. 705-718, (1998)
[3]  
Kidwell C.S., Liebeskind D.S., Starkman S., Saver J.L., Trends in acute ischemic stroke trials through the 20th century, Stroke, 32, pp. 1349-1359, (2001)
[4]  
DeGraba T.J., Pettigrew L.C., Why do neuroprotective drugs work in animals but not humans?, Neurol. Clin., 18, pp. 475-493, (2000)
[5]  
Grotta J., Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy, J. Intern. Med., 237, pp. 89-94, (1995)
[6]  
Felberg R.A., Burgin W.S., Grotta J.C., Neuroprotection and the ischemic vascade, CNS Spectrums, 5, pp. 52-58, (2000)
[7]  
Clark W., Reperfusion injury in stroke, Emedicine J., 2, pp. 15-18, (2001)
[8]  
Stroke Therapy Academic Industry Roundtable Recommendations for standards regarding preclinical neuroprotective and restorative drug development, Stroke, 30, pp. 2752-2758, (1999)
[9]  
De Keyser J., Sulter G., Luiten P.G., Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?, Trends Neurosci., 22, pp. 535-540, (1999)
[10]  
Gorelick P.B., Neuroprotection in acute ischemic stroke: A tale of for whom the bell tolls?, Lancet, 355, pp. 1925-1926, (2000)
12345678